EUVIMEDEUVIMED entdecken
Fallbericht

Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC

Frank Jordan, Martin Trepel, Rainer Claus

Clinical Colorectal Cancer · 2022-09 · 21 (3) · e148-e151

DOI: 10.1016/j.clcc.2022.01.003 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Colorectal Cancer, 2022-09. Verfasst von Frank Jordan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Center Augsburg, University Medical Center Augsburg, Medical Department, Division of Hematology and Oncology, Germany. Electroni…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune-Checkpoint-inhibitors (ICIs) are approved in first line therapy of microsatellite-instable, deficient miss-match-repair (MSI-H-dMMR) metastatic colorectal cancer (mCRC), and in second line after standard chemotherapy. Evidence supporting immunotherapy after immunotherapy is scarce. CASE REPORT: This case report highlights the course of a heavily pretreated patient with MSI-H mCRC with progression after multiple local therapies, standard chemotherapies and pembrolizumab. After 4 cycles of ipilimumab and nivolumab followed by nivolumab-maintenance he achieved a long-lasting disease control of 22 months. After further subsequent progression he regained immune mediated disease control by a second "boost" of ipilimumab. CONCLUSION: Re-exposition with ipilimumab is a potential option to restore immune-mediated-disease-control in patients with preceding long-lasting response to ipilimumab/nivolumab and with dMMR-tumors. The clinical situation of progress after long-lasting disease control on ICIs becomes more common and is an opportunity to investigate potential strategies for restoring immune mediated disease control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsColorectal NeoplasmsDNA Mismatch RepairHumansImmunotherapyIpilimumabMaleMicrosatellite InstabilityNivolumab

Stichwörter der Autor:innen

Ipilimumab after ipilimumabIpilimumab-boostMSI-H metastatic colorectal cancerRe-exposition ipilimumabReinduction ipilimumab

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Comprehensive Cancer Center Augsburg, University Medical Center Augsburg, Medical Department, Division of Hematology and Oncology, Germany. Electronic address: frank.jordan@uk-augsburg.de.
  • Comprehensive Cancer Center Augsburg, University Medical Center Augsburg, Medical Department, Division of Hematology and Oncology, Germany.

Zitieren

APA

Jordan, F., Trepel, M., & Claus, R. (2022). Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC. Clinical Colorectal Cancer, 21(3), e148-e151. https://doi.org/10.1016/j.clcc.2022.01.003

Vancouver

Jordan F, Trepel M, Claus R. Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC. Clinical Colorectal Cancer. 2022;21(3):e148-e151. doi:10.1016/j.clcc.2022.01.003

BibTeX
@article{Jordan2022,
  author = {Jordan, Frank and Trepel, Martin and Claus, Rainer},
  title = {Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC},
  journal = {Clinical Colorectal Cancer},
  year = {2022},
  volume = {21},
  number = {3},
  pages = {e148--e151},
  doi = {10.1016/j.clcc.2022.01.003}
}
Kostenlos starten →